CD152 (CTLA-4, Cytotoxic T-lymphocyte Protein 4, Cytotoxic T-lymphocyte-associated Antigen 4, Ctla4)

Size

£863.00

SKU:: 506138
Purity:: Purified by Protein G affinity chromatography from hybridoma culture supernatant. Endotoxin: ≤0.1EU/ug (LAL)
Storage Conditions:: -20°C
Supplier:: United States Biological
Host:: Rat
Immunogen:: Recombinant protein corresponding to Ala36-Phe161 of mouse CTLA-4, expressed in NSO cells.
Clone:: 63828
Format:: Supplied as a lyophilized powder in PBS, 5% trehalose. Reconstitute with 200ul sterile PBS.
Extra Details:: CTLA-4 and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CTLA-4 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CTLA-4 and CD28 are composed of a single Ig V‑like extracellular domain, a transmembrane domain and an intracellular domain. CTLA-4 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. The genes encoding these two molecules are closely linked on human chromosome 2. CTLA-4 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CTLA-4 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CTLA-4 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with 20-100-fold higher affinity than CD28. The physiological role of CTLA-4 in T cell costimulation is currently being studied. Applications: Suitable for use in Neutralization, Western Blot and Flow Cytometry. Other applications not tested. Recommended Dilutions: Flow Cytometry: 2.5ug/10e6 cells using mouse splenocytes treated with ConA Western Blot: 1ug/ml using recombinant mouse CTLA‑4 Fc Chimera under non-reducing conditions only Neutralization: Measured by its ability to neutralize CTLA‑4 inhibition of B7‑1/CD80-induced IL‑2 secretion in the Jurkat human acute T cell leukemia cell line. Linsley, P. et al. (1990) Proc. Natl. Acad. Sci. USA 87:5031. The Neutralization Dose (ND50) is typically 2.5-10ug/ml in the presence of 1ug/ml Recombinant Mouse CTLA‑4 Fc Chimera, 3ug/mL Recombinant Human B7‑1/CD80 Fc Chimera, and 10ug/mL PHA. Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Shipping Conditions:: Blue Ice